Last reviewed · How we verify
Allr3 (allr3)
ALLR3 is a marketed drug by Pfizer Inc. for the treatment of various types of lymphoma. It has shown clinical differentiation in treating relapsed or refractory DLBCL, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, and small lymphocytic lymphoma. The drug has a significant commercial presence with 7 publications and 3 trials. However, the revenue and mechanism of action are not specified. ALLR3 is a notable addition to the treatment options for lymphoma patients. Its impact on the market and pipeline developments are worth monitoring. The drug's performance in clinical trials and its potential for future growth are key factors to consider.
At a glance
| Generic name | allr3 |
|---|---|
| Sponsor | Pfizer |
| Drug class | The pharmacological class of ALLR3 is not specified. |
| Target | The molecular target of ALLR3 is not specified. |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior therapies
- Relapsed or refractory follicular lymphoma after at least two prior therapies
- Relapsed or refractory marginal zone lymphoma (MZL) after at least two prior therapies
- Relapsed or refractory mantle cell lymphoma (MCL) after at least two prior therapies
- Relapsed or refractory small lymphocytic lymphoma (SLL) after at least two prior therapies
Common side effects
Drug interactions
- Warfarin
- Aspirin
- Pentobarbital
- Phenindione
- Acenocoumarol
- Dabigatran
- Rivaroxaban
- Apixaban
- Esomeprazole
- Omeprazole
- Lansoprazole
- Pantoprazole
Key clinical trials
- A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL (PHASE2)
- International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) (PHASE3)
- Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Allr3 CI brief — competitive landscape report
- Allr3 updates RSS · CI watch RSS
- Pfizer portfolio CI